Amitabh Chandra, Craig Garthwaite
Abstract
Contrary to the hopes of its supporters, indication-based drug pricing will result in higher prices for patients who benefit the most from a given drug, higher utilization by patients who benefit least, higher overall spending, and higher manufacturer profits.
OpenAlex reports 80 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Contrary to the hopes of its supporters, indication-based drug pricing will result in higher prices for patients who benefit the most from a given drug, higher utilization by patients who benefit least, higher overall spending, and higher manufacturer profits.
Key concepts: Drug pricing, Medicine, Drug prices, Drug, Actuarial science, Public economics, Economics, Pharmacology